- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04373044
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the efficacy of baricitinib combined with antiviral therapy in participants with COVID-19-related moderate and severe disease in terms of reduction of the proportion of participants requiring invasive mechanical ventilation or dying or requiring anti-IL6 monoclonal antibodies compared to that seen with antiviral alone within 60 days.
SECONDARY OBJECTIVES:
I. To describe the clinical findings in a cohort of symptomatic COVID-19-infected participants.
II. To test whether cytokine signatures predict progression to invasive ventilatory support or death.
III. To describe adverse events (AEs) associated with baricitinib when administered at 4mg in combination with antivirals.
EXPLORATORY OBJECTIVES:
I. Describe the decay in quantitative viral burden from saliva samples collected sequentially under treatment with baricitinib in combination with antivirals.
II. To obtain preliminary data on efficacy and tolerability of baricitinib in combination with antivirals in participants with cancer.
OUTLINE: Patients are randomized to 1 of 2 groups.
GROUP I: Patients receive baricitinib orally (PO) daily, and standard of care hydroxychloroquine PO three times daily (TID). Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
GROUP II: Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Patients are followed for 60 days after enrollment to treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, United States, 90033
- Los Angeles County-USC Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Positive polymerase chain reaction (PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in a respiratory tract sample OR positive anti-SARS CoV2 IgM antibody test that is approved by Food and Drug Administration (FDA) or allowed under an emergency use authorization; either result obtained within 5 days prior to study entry
- Cough and/or pneumonia on chest imaging
- Moderate disease with risk factor(s): Peripheral capillary oxygen saturation (SpO2) >= 92% on room air with one of the following risk factors for development of severe disease: age >= 60 years, receiving medication for hypertension, diagnosed diabetes mellitus, known cardiac disease, chronic lung disease, obesity (body mass index [BMI] >= 35 kg/m^2), active malignancy, immunosuppression (receiving biologics or glucocorticoids >= 20 mg/d prednisone equivalent for > 2 weeks)
- Severe disease: SpO2 =< 92% on room air
Ability to understand and the willingness to sign a written informed consent. Adults not competent to consent will be enrolled with the use of an appropriate legally authorized representative (per California Code, Health and Safety Code - HSC)
- FDA regulations generally require that the informed consent of a participant be documented by the use of a written consent form approved by the IRB and signed and dated by the participant or the participant's legally authorized representative at the time of consent (21 case form report [CFR] 50.27[a]). In light of COVID-19 infection control measures, the following procedure would satisfy documentation of this requirement if the participant signing the informed consent is in COVID-19 isolation. If the technology is available, electronic methods of obtaining informed consent will be taken. The electronic consent and Health Insurance Portability and Accountability Act (HIPAA) forms will be uploaded and available through REDCap
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of therapy. NOTE: Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Women of child-bearing potential should use highly effective methods of birth control. These are those methods of contraception, alone or in combination, that result in a low failure rate (i.e, less than 1% per year) when used consistently and correctly
Exclusion Criteria:
- Mechanical ventilation, high-flow nasal oxygen, biphasic positive airway pressure (BiPAP)
- Venous thromboembolism within 12 weeks or previously diagnosed thrombophilic conditions or conditions that increase the risk of thrombosis. Individuals with > 1 episode of venous thromboembolism or pulmonary embolism in the past will also be excluded
- Prior receipt of other immunomodulatory drugs (e.g., any JAK inhibitors, immunomodulatory biologics, or other immunomodulatory investigational products) within 14 days prior to enrollment
- Current treatment with probenecid
- Known infection with human immunodeficiency syndrome (HIV), or active infection with hepatitis B or hepatitis C
- Participant with known active or latent tuberculosis infection
- Pregnancy and lactation
Any serious acute infections or known active or latent tuberculosis
- All enrolled participants will be screened for latent tuberculosis infection by testing QuantiFERON-TB Gold Plus, but a documented negative test will not be required prior to entry. If a participant is found to have positive QuantiFERON that results after enrollment, baricitinib will be discontinued
- Solid organ transplant recipient
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal
- Absolute neutrophil count < 1000/mm^3
- Absolute lymphocyte count < 200/mm^3
- Hemoglobin < 8 g/dl
- Estimated glomerular filtration rate (GFR) < 30 mL/min/1.73 m^2
- Any medical condition in the opinion of the investigator that would place the participant at undue high risk for participation in the trial
- Hypersensitivity to the active substance or to any of the excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm II (placebo, antiviral therapy)
Patients receive placebo PO daily, and standard of care hydroxychloroquine PO TID.
Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
|
Given PO
Given Po
|
Experimental: Treatment (baricitinib, antiviral therapy)
Patients receive baricitinib PO daily, and standard of care hydroxychloroquine PO TID.
Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
|
Given PO
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients requiring invasive mechanical ventilation or dying
Time Frame: Up to 14 days
|
Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe all the clinical findings in a cohort of symptomatic coronavirus disease 2019 (COVID-19)-infected subjects.
The collected data will also be graphically presented in boxplots, histograms, and scatter plots.
Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity, will be made.
Group comparisons will be made using either the parametric tests such as t-test and analysis of variance (ANOVA), or the non-parametric statistical method such as Wilcoxon and Kruskal-Wallis tests for continuous variable and Chi-square test for categorical variables.
Point estimates, along with the corresponding p-values and 95% confidence intervals will be reported.
|
Up to 14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of clinical features (vitals signs - body temperature)
Time Frame: Up to 28 days
|
Body temperature will be measured in degrees Fahrenheit using an automated thermometer.
|
Up to 28 days
|
Identification of clinical features (vital signs - respiratory rate)
Time Frame: Up to 28 days
|
Respiratory rate in times/minute
|
Up to 28 days
|
Identification of clinical features (vital signs - heart rate)
Time Frame: Up to 28 days
|
Heart rate in beats/minute
|
Up to 28 days
|
Identification of clinical features (vital signs - blood pressure)
Time Frame: Up to 28 days
|
Blood pressure in mmHg
|
Up to 28 days
|
Identification of clinical features (Imaging)
Time Frame: Up to 28 days
|
Chest X-ray or pulmonary computed tomography (CT) will be performed
|
Up to 28 days
|
Identification of clinical features (Lab - White Blood Count)
Time Frame: Up to 28 days
|
Assessment via standard blood chemistry and metabolic panel
|
Up to 28 days
|
Identification of clinical features (Lab - Absolute Lymphocyte Count)
Time Frame: Up to 28 days
|
Assessment via standard blood chemistry and metabolic panel
|
Up to 28 days
|
Identification of clinical features (Lab - Hemoglobin)
Time Frame: Up to 28 days
|
Assessment via standard blood chemistry and metabolic panel
|
Up to 28 days
|
Identification of clinical features (Lab - Creatinine)
Time Frame: Up to 28 days
|
Assessment via standard blood chemistry and metabolic panel
|
Up to 28 days
|
Identification of biomarkers (C-reactive protein)
Time Frame: Up to 14 days
|
CRP is assessed by routinely used determination of CRP.
|
Up to 14 days
|
Identification of biomarkers (Interleukin-6)
Time Frame: Up to 14 days
|
IL-6 levels will be assessed using commercial ELISA method
|
Up to 14 days
|
Identification of biomarkers (Tumor Necrosis Factor-alpha)
Time Frame: Up to 14 days
|
Tumor Necrosis Factor-alpha as measured in hospital laboratory
|
Up to 14 days
|
Identification of adverse events
Time Frame: Up to 14 days
|
Descriptive statistics, including means, standard deviations, and ranges for continuous variables, as well as percentages and frequencies for categorical variables, will be provided to describe all the clinical findings in a cohort of symptomatic COVID-19-infected subjects.
The collected data will also be graphically presented in boxplots, histograms, and scatter plots.
Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity, will be made.
Group comparisons will be made using either the parametric tests such as t-test and ANOVA, or the non-parametric statistical method such as Wilcoxon and Kruskal-Wallis tests for continuous variable and Chi-square test for categorical variables.
Point estimates, along with the corresponding p-values and 95% confidence intervals will be reported.
|
Up to 14 days
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Measurement of COVID19 viral burden
Time Frame: Up to 14 days
|
Up to 14 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Heinz-Josef Lenz, MD, University of Southern California
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Occupational Diseases
- COVID-19
- Laboratory Infection
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Hydroxychloroquine
Other Study ID Numbers
- 0S-20-3 (Other Identifier: USC / Norris Comprehensive Cancer Center)
- P30CA014089 (U.S. NIH Grant/Contract)
- NCI-2020-02685 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic COVID-19 Infection Laboratory-Confirmed
-
City of Hope Medical CenterNational Cancer Institute (NCI); California Institute for Regenerative Medicine...Active, not recruitingAsymptomatic COVID-19 Infection Laboratory-Confirmed | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnSymptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Emory UniversityNational Cancer Institute (NCI)Active, not recruitingSevere Acute Respiratory Syndrome | Pneumonia | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-Confirmed
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)SuspendedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
Red Queen Therapeutics, Inc.PPDCompletedCOVID-19 | Infectious Disease | SARS CoV 2 Infection | Symptomatic COVID-19 Infection Laboratory-ConfirmedUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | BK Virus Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed | Adenovirus Infection | Cytomegaloviral Infection | JC Virus InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 Infection | Symptomatic COVID-19 Infection Laboratory-Confirmed | COVID-19-Associated Acute Respiratory Distress SyndromeUnited States
Clinical Trials on Hydroxychloroquine
-
Cambridge University Hospitals NHS Foundation TrustUnknown
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnMyelodysplastic Syndromes | Progressive DiseaseUnited States
-
Health Institutes of TurkeyCompleted
-
Peng Wang, MD PhDCompleted
-
University of MichiganCures Within ReachRecruitingRetinitis PigmentosaUnited States
-
University Hospital, MontpellierTerminatedCoronavirus Infection | Pneumonia, ViralFrance
-
Assistance Publique - Hôpitaux de ParisCompletedSARS-CoV-2 InfectionFrance
-
Hospital do CoracaoHospital Israelita Albert Einstein; Hospital Sirio-Libanes; Brazilian Research... and other collaboratorsCompletedCoronavirus InfectionsBrazil
-
Ravi Amaravadi, MDTerminatedCOVID-19United States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States